Loading
Archives of Pharmacology and Therapeutics
ISSN: 2688-9609
Off Label Use as an Indicator of Therapeutic Need in Pediatrics
Unapproved use of an approved drug is called “off-label” use. In line with European Medicine Agency’s pharmacovigilance directive, off-label use “relates to situations where a medicinal product is intentionally used for a medical purpose not in accordance with the authorised product information (SmPC).
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p1-4 | DOI: 10.33696/Pharmacol.4.036The Role of the General Practitioner in Vaccination against COVID-19
The SARS-CoV-2 virus, responsible for covid-19, had an animal origin and jumped to humans in 2019. In 2020 alone, COVID-19 infected almost 100 million people around the planet and ended with the lives of 2 million people. The development in a very short space of time, of vaccines against COVID-19, in response to the urgency of the pandemic, is a transcendental milestone in the history of medicine.
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p5-7 | DOI: 10.33696/Pharmacol.4.037POSTCOVID-19WAR Era, Interaction between Cancer-Hematologic Disorders- Diabetes Significantly Increased by COVID-19 Variants, Aggressively
Understanding the mechanism of bidirectional interaction between different angles of the death triangle is a lifesaving novel idea that I invented in 2018. Platelet hyperactivity and dysfunction in diabetes and cancer patients were already known facts [1] but whether different COVID-19 variants could activate and/or accelerate death triangle machinery?
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p8-10 | DOI: 10.33696/Pharmacol.4.038Keeping Ready against Omicron and Future Variants: Can Ivermectin Prophylactic Effects Improve the Vaccination Effects against COVID-19?
The standard treatment options for Coronavirus disease 2019 (COVID-19) remain challenging despite community vaccinations and reduced mortality. As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus continues to evolve and new strains emerge, diversity in the use of existing antiviral drugs has become a crucial therapeutic tool in combating the COVID-19 epidemic.
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p11-17 | DOI: 10.33696/Pharmacol.4.039Proto-oncogenes Crosstalk, Feedback and Expression, and Anticancer Drugs Resistance
Proto-oncogenes like C-MYC, EGFR and others have physiological function in regeneration, wound and any stressfully injury to maintain tissue echotexture and healing. Notably, these growth factors work together and had life span to retain to basal level after tissue remodeling and retain its function like what happen in partial hepatectomy.
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p18-21 | DOI: 10.33696/Pharmacol.4.040Reflections on COVID-19 Pharmacological Treatment and Beyond: Beware of “Salads” with Many Ingredients but Low Scientific Content
The pandemic triggered by SARS-CoV-2 has changed since that first case in Wuhan in 2019. We currently have efficient vaccines that have allowed us to return to our daily activities. But, SARS-CoV-2 remains a public health emergency of international concern.
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p22-24 | DOI: 10.33696/Pharmacol.4.041Application of Halides Complexes of Ruthenium (II) in Metallopharmaceuticals and in Material Science: Part-I
Ruthenium readily forms coordinate-complexes and these complexes have their applications in diverse fields. A survey of literature shows that designing of new ligands that can be complexed with Ruthenium (Ru) in various oxidation states can lead to development of new materials with diverse applications.
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p25-35 | DOI: 10.33696/Pharmacol.4.042From Data to Knowledge: A Mini-Review on Molecular Network Modeling and Analysis for Therapeutic Target Discovery
Successful drug development is a risky and lengthy process that can take over ten years and consume billions of dollars. Target discovery is a critical stage of drug development for the identification of key molecules and pathways that can be targeted by novel therapeutics to find more effective treatments. Due to the rapid development in artificial intelligence and machine learning techniques over the past decade
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p36-43 | DOI: 10.33696/Pharmacol.4.043Dose-dependent Oxidative Damage of Molnupiravir (Antiviral Drug for Treatment of COVID-19) in Lung, Liver, Heart, and Kidney Tissues in Rats
Molnupiravir (MOL) is an orally absorbed prodrug of the ribonucleoside analogue N-hydroxycytidine, which has in vitro activity against several coronaviruses, including SARS-CoV-1 and 2. It remains to be seen whether long term MOL has serious side effects. The side effects of MOL, which was the first to be allowed for oral use during the pandemic process, are not yet fully known. In this study, it was aimed to investigate the the mechanisms of possible dose-dependent damage on liver, lung, heart, and kidney tissues.
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p44-52 | DOI: 10.33696/Pharmacol.4.044Recent Advances in Diagnosing and Treating Helicobacter pylori through Botanical Extracts and Advanced Technologies
Helicobacter pylori (H. pylori) infection is a major global health concern, with an estimated 50% of the world's population infected. The bacterium colonizes the stomach and is associated with a range of gastrointestinal diseases, including chronic gastritis, peptic ulcers, and gastric cancer. The current standard of care for H. pylori infection involves a combination of antibiotics and proton pump inhibitors (PPIs), but the widespread use of antibiotics has led to the development of antibiotic-resistant strains of H. pylori, making treatment more difficult. Recent advances in diagnostic strategies include the use of non-invasive tests and serological biomarkers.
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p53-66 | DOI: 10.33696/Pharmacol.4.045Pharmacology of Berberine and Its Metabolites, Is It the Natures Ozempic or Imatinib?
Berberine, a naturally occurring alkaloid, is widely explored for several health benefits, including weight management and metabolic disorders. The major pharmacological action of berberine is reported to be by activation of AMP-activated protein kinase, while its other clinical outcomes are devoid of clear mechanism of action/s. Hence in this study a detailed pharmacology of berberine and its two major metabolites (berberrubine, and jatrorrhizine) in humans was evaluated using well established Insilco tools.
Arch Pharmacol Ther, 2023, Volume 5, Issue 1, p67-81 | DOI: 10.33696/Pharmacol.4.046Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.